pharmaceuticals

Growth becoming harder to achieve

At a recent American Society for Clinical Oncology (ASCO) conference investors were able to review progress in immunotherapy clinical trials. The progress is positive. Incyte, for one, presented improved patient response rates in five types of cancer...

Views from WHEB Asset Management

BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.

Head of Investment at BB Biotech, Daniel Koller, discusses sector growth and the attractive valuations of fast growing companies.

Previously warned on pharma dividends

A Q&A with BB Biotech's Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities.

Despite the uncertainty on the political front and the macroeconomic unknowns, the biotech sector's fundamentals have remained solid.

Scientific breakthroughs the key driver